Search

Your search keyword '"Sarasquete, M. E."' showing total 42 results
Start Over Author "Sarasquete, M. E."
42 results on '"Sarasquete, M. E."'

1. MIPI53. A NEW PROGNOSTIC INDEX FOR MANTLE CELL LYMPHOMA

Author

Boente, M. Bastos, primary, Sánchez, M. Alcoceba, additional, Bailón, A. Navarro, additional, Herrera, A. Medina, additional, Álvarez, M. García, additional, Sarasquete, M. E. Alonso, additional, Santos, C. Chillón, additional, Echevarría, A. Balanzategui, additional, Gómez, A. Antón, additional, Niño, J., additional, Loizaga, I. de la Torre, additional, Bedera, N. H. Vidaña, additional, Sánchez, R. Maldonado, additional, Ruano, M. Hernández, additional, Sánchez, S. M. Lucas, additional, Villares, M. I. Sánchez, additional, González, A. I. Sánchez, additional, González de la Calle, V., additional, Díaz, M. González, additional, Sánchez, C. Jiménez, additional, Sanz, R. García, additional, and García‐Sancho, A. Martín, additional

Published
2023
Full Text
View/download PDF

2. Molecular characterization of diffuse large‐B cell lymphoma by liquid biopsy at diagnosis and during follow‐up. OBO "Euroclonality‐NGS group" & "Grupo Colaborativo Linfomas y SLP de CyL"

Author

Alcoceba, M., primary, Stewart, J. P., additional, Álvarez, M. G., additional, Jiménez, C., additional, Medina, A., additional, Chillón, M. C., additional, Gazdova, J., additional, Blanco, Ó., additional, Díaz, L. G., additional, Villanueva, J. G., additional, Tamayo, P., additional, Esteban, C., additional, Arias, P., additional, Díaz, F. J., additional, Peñarrubia, M. J., additional, Fernández, S., additional, Cabero, A., additional, Vidriales, M. B., additional, Caballero, M. D., additional, González, M., additional, García‐Sanz, R., additional, Gutiérrez, N. C., additional, González, D., additional, García‐Sancho, A. Martín, additional, and Sarasquete, M. E., additional

Published
2023
Full Text
View/download PDF

4. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

Author

Paíno, T, Paiva, B, Sayagués, J M, Mota, I, Carvalheiro, T, Corchete, L A, Aires-Mejía, I, Pérez, J J, Sanchez, M L, Barcena, P, Ocio, E M, San-Segundo, L, Sarasquete, M E, García-Sanz, R, Vidriales, M-B, Oriol, A, Hernández, M-T, Echeveste, M-A, Paiva, A, Blade, J, Lahuerta, J-J, Orfao, A, Mateos, M-V, Gutiérrez, N C, and San-Miguel, J F

Published
2015
Full Text
View/download PDF

5. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

Author

Puig, N, Sarasquete, M E, Balanzategui, A, Martínez, J, Paiva, B, García, H, Fumero, S, Jiménez, C, Alcoceba, M, Chillón, M C, Sebastián, E, Marín, L, Montalbán, M A, Mateos, M V, Oriol, A, Palomera, L, de la Rubia, J, Vidriales, M B, Bladé, J, Lahuerta, J J, González, M, Miguel, J F S, and García-Sanz, R

Published
2014
Full Text
View/download PDF

10. Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders

Author

Stewart, J, Gazdova, J, Darzentas, N, Wren, D, Proszek, P, Fazio, G, Songia, S, Alcoceba, M, Sarasquete, M, Villarese, P, Van Der Klift, M, Heezen, K, Mccafferty, N, Pal, K, Catherwood, M, Kim, C, Srivastava, S, Kroeze, L, Hodges, E, Stamatopoulos, K, Klapper, W, Genuardi, E, Ferrero, S, Van Den Brand, M, Cazzaniga, G, Davi, F, Sutton, L, Garcia-Sanz, R, Groenen, P, Macintyre, E, Bruggemann, M, Pott, C, Langerak, A, Gonzalez, D, Stewart J. P., Gazdova J., Darzentas N., Wren D., Proszek P., Fazio G., Songia S., Alcoceba M., Sarasquete M. E., Villarese P., Van Der Klift M. Y., Heezen K. C., McCafferty N., Pal K., Catherwood M., Kim C. S., Srivastava S., Kroeze L. I., Hodges E., Stamatopoulos K., Klapper W., Genuardi E., Ferrero S., Van Den Brand M., Cazzaniga G., Davi F., Sutton L. -A., Garcia-Sanz R., Groenen P. J. T. A., Macintyre E. A., Bruggemann M., Pott C., Langerak A. W., Gonzalez D., Stewart, J, Gazdova, J, Darzentas, N, Wren, D, Proszek, P, Fazio, G, Songia, S, Alcoceba, M, Sarasquete, M, Villarese, P, Van Der Klift, M, Heezen, K, Mccafferty, N, Pal, K, Catherwood, M, Kim, C, Srivastava, S, Kroeze, L, Hodges, E, Stamatopoulos, K, Klapper, W, Genuardi, E, Ferrero, S, Van Den Brand, M, Cazzaniga, G, Davi, F, Sutton, L, Garcia-Sanz, R, Groenen, P, Macintyre, E, Bruggemann, M, Pott, C, Langerak, A, Gonzalez, D, Stewart J. P., Gazdova J., Darzentas N., Wren D., Proszek P., Fazio G., Songia S., Alcoceba M., Sarasquete M. E., Villarese P., Van Der Klift M. Y., Heezen K. C., McCafferty N., Pal K., Catherwood M., Kim C. S., Srivastava S., Kroeze L. I., Hodges E., Stamatopoulos K., Klapper W., Genuardi E., Ferrero S., Van Den Brand M., Cazzaniga G., Davi F., Sutton L. -A., Garcia-Sanz R., Groenen P. J. T. A., Macintyre E. A., Bruggemann M., Pott C., Langerak A. W., and Gonzalez D.

Abstract

Current diagnostic standards for lymphoproliferative disorders include multiple tests for detection of clonal immunoglobulin (IG) and/or T-cell receptor (TCR) rearrangements, translocations, copy-number alterations (CNAs), and somatic mutations. The EuroClonality-NGS DNA Capture (EuroClonality-NDC) assay was designed as an integrated tool to characterize these alterations by capturing IGH switch regions along with variable, diversity, and joining genes of all IG and TCR loci in addition to clinically relevant genes for CNA and mutation analysis. Diagnostic performance against standard-of-care clinical testing was assessed in a cohort of 280 B-and T-cell malignancies from 10 European laboratories, including 88 formalin-fixed paraffin-embedded samples and 21 reactive lesions. DNA samples were subjected to the EuroClonality-NDC protocol in 7 EuroClonality-NGS laboratories and analyzed using a bespoke bioinformatic pipeline. The EuroClonality-NDC assay detected B-cell clonality in 191 (97%) of 197 B-cell malignancies and T-cell clonality in 71 (97%) of 73 T-cell malignancies. Limit of detection (LOD) for IG/TCR rearrangements was established at 5% using cell line blends. Chromosomal translocations were detected in 145 (95%) of 152 cases known to be positive. CNAs were validated for immunogenetic and oncogenetic regions, highlighting their novel role in confirming clonality in somatically hypermutated cases. Single-nucleotide variant LOD was determined as 4% allele frequency, and an orthogonal validation using 32 samples resulted in 98% concordance. The EuroClonality-NDC assay is a robust tool providing a single end-To-end workflow for simultaneous detection of B-and T-cell clonality, translocations, CNAs, and sequence variants.

Published
2021

12. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Author

Medina, Alejandro, Puig, N., Flores-Montero, Juan, Jimenez, C., Sarasquete, M. E., García-Álvarez, M., Prieto-Conde, I., Chillon, C., Alcoceba, Miguel, Gutierrez, N. C., Oriol, Albert, Rosinol, L., Bladé Creixenti, Juan, Gironella, Mercedes, Hernandez, M. T., Gonzalez-Calle, V., Cedena, María Teresa, Paiva, Bruno, San-Miguel, J., Lahuerta, J. J., Mateos, M. V., Martínez-López, Joaquín, Orfao, Alberto, Gonzalez, M, García-Sanz, Ramón, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Medina A, Puig N, Jimenez C, Sarasquete ME, Garcia-Alvarez M] Departamento de Hematología, Hospital Universitario de Salamanca (HUSA/ IBSAL), CIBERONC, CIC-IBMCC (USAL-CSIC), Salamanca, Spain. [Flores-Montero J] Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain. [Gironella M] Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Nucleòtids - Anàlisi, Neoplasm, Residual, Myeloma, lcsh:RC254-282, Disease-Free Survival, Article, DNA sequencing, EuroFlow, Internal medicine, medicine, neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple [ENFERMEDADES], Humans, In patient, Survival rate, Multiple myeloma, Proportional hazards model, business.industry, Mieloma múltiple, Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma [DISEASES], High-Throughput Nucleotide Sequencing, Hematology, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Flow Cytometry, medicine.disease, Minimal residual disease, técnicas de investigación::técnicas genéticas::análisis de secuencias [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Survival Rate, Transplantation, Investigative Techniques::Genetic Techniques::Sequence Analysis [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Risk factors, Female, Multiple Myeloma, business, Follow-Up Studies
Abstract

© The Author(s) 2020., Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after transplantation in 106 myeloma patients using a commercial next-generation sequencing (NGS) strategy (LymphoTrack®), and compared the results with nextgeneration flow (NGF, EuroFlow). The use of different marrow pulls and the need of concentrating samples for NGS biased the applicability for MRD evaluation and favored NGF. Despite that, correlation between NGS and NGF was high (R2 = 0.905). The 3-year progression-free survival (PFS) rates by NGS and NGF were longer for undetectable vs. positive patients (NGS: 88.7% vs. 56.6%; NGF: 91.4% vs. 50%; p < 0.001 for both comparisons), which resulted in a 3-year overall survival (OS) advantage (NGS: 96.2% vs. 77.3%; NGF: 96.6% vs. 74.9%, p < 0.01 for both comparisons). In the Cox regression model, NGS and NGF negativity had similar results but favoring the latter in PFS (HR: 0.20, 95% CI: 0.09–0.45, p < 0.001) and OS (HR: 0.21, 95% CI: 0.06–0.75, p = 0.02). All these results reinforce the role of MRD detection by different strategies in patient prognosis and highlight the use of MRD as an endpoint for multiple myeloma treatment.

Published
2020

13. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

Author

Medina, Alejandro, Jiménez, C., Sarasquete, M. E., González, M., Chillón, M. Carmen, Balanzategui, A., Prieto-Conde, I., García-Álvarez, M., Puig, N., González-Calle, Verónica, Alcoceba, Miguel, Cuenca, I., Barrio, S., Escalante, F., Gutiérrez, N. C., Gironella, Mercedes, Hernández, M. T., Sureda, A., Oriol, Albert, Bladé Creixenti, Juan, Lahuerta, J. J., San Miguel, J. F., Mateos, M. V., Martínez-López, J., Calasanz, M.J, García-Sanz, Ramón, Universitat Autònoma de Barcelona, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), Fundación CRIS contra el Cáncer, Fundacion de la Sociedad Española de Hematología y Hemoterapia, Universidad de Salamanca, European Commission, Institut Català de la Salut, [Medina A, Jiménez C, Sarasquete ME, González M, Chillón MC, Balanzategui A] Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain. [Gironella M] Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Oncology, Male, Immunoglobulin Variable Region, Myeloma, Disease, fenómenos genéticos::regulación de la expresión génica::regulación de la expresión génica neoplásica [FENÓMENOS Y PROCESOS], Pathogenesis, Multiple myeloma, Genetics research, Aged, 80 and over, Gene Rearrangement, Univariate analysis, biology, Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma [DISEASES], Hematology, Middle Aged, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Gene Expression Regulation, Neoplastic, Multigene Family, Female, Antibody, Immunoglobulin Heavy Chains, Multiple Myeloma, Adult, medicine.medical_specialty, Cèl·lules B, Genetic Phenomena::Gene Expression Regulation::Gene Expression Regulation, Neoplastic [PHENOMENA AND PROCESSES], Somatic hypermutation, lcsh:RC254-282, Article, Internal medicine, Regulació genètica, medicine, Biomarkers, Tumor, Humans, neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple [ENFERMEDADES], Gene, Aged, B cells, business.industry, Gene Expression Profiling, Mieloma múltiple, medicine.disease, Transplantation, biology.protein, business, Follow-Up Studies
Abstract

Multiple myeloma is a heterogeneous disease whose pathogenesis has not been completely elucidated. Although B-cell receptors play a crucial role in myeloma pathogenesis, the impact of clonal immunoglobulin heavy-chain features in the outcome has not been extensively explored. Here we present the characterization of complete heavy-chain gene rearrangements in 413 myeloma patients treated in Spanish trials, including 113 patients characterized by next-generation sequencing. Compared to the normal B-cell repertoire, gene selection was biased in myeloma, with significant overrepresentation of IGHV3, IGHD2 and IGHD3, as well as IGHJ4 gene groups. Hypermutation was high in our patients (median: 8.8%). Interestingly, regarding patients who are not candidates for transplantation, a high hypermutation rate (≥7%) and the use of IGHD2 and IGHD3 groups were associated with improved prognostic features and longer survival rates in the univariate analyses. Multivariate analysis revealed prolonged progression-free survival rates for patients using IGHD2/IGHD3 groups (HR: 0.552, 95% CI: 0.361−0.845, p = 0.006), as well as prolonged overall survival rates for patients with hypermutation ≥7% (HR: 0.291, 95% CI: 0.137−0.618, p = 0.001). Our results provide new insights into the molecular characterization of multiple myeloma, highlighting the need to evaluate some of these clonal rearrangement characteristics as new potential prognostic markers., This work was partially supported by the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness PI15/01956, CIBERONC-CB16/12/00233, and “Una manera de hacer Europa” (Innocampus; CEI-2010-1-0010)”. M.G.-A., I.P.-C., and C.J. are supported by the Fundación Española de Hematología y Hemoterapia (FEHH, co-funded by Fundación Cris in the latter case), A.M. by the European Social Fund and the Spanish Education Council through the University of Salamanca, and M.E.S. by the ISCIII (CPII18/00028). All Spanish funding is co-sponsored by the European Union FEDER program.

Published
2020

20. From Waldenström’s macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation

Author

Jiménez, C, primary, Alonso-Álvarez, S, additional, Alcoceba, M, additional, Ordóñez, G R, additional, García-Álvarez, M, additional, Prieto-Conde, M I, additional, Chillón, M C, additional, Balanzategui, A, additional, Corral, R, additional, Marín, L A, additional, Gutiérrez, N C, additional, Puig, N, additional, Sarasquete, M E, additional, González, M, additional, and García-Sanz, R, additional

Published
2017
Full Text
View/download PDF

21. Design and application of a 23-gene panel by next-generation sequencing for inherited coagulation bleeding disorders

Author

Bastida, J. M., primary, del Rey, M., additional, Lozano, M. L., additional, Sarasquete, M. E., additional, Benito, R., additional, Fontecha, M. E., additional, Fisac, R., additional, García-Frade, L. J., additional, Aguilar, C., additional, Martínez, M. P., additional, Pardal, E., additional, Aguilera, C., additional, Pérez, B., additional, Ramos, R., additional, Cardesa, M. R., additional, Martin-Antorán, J. M., additional, Silvestre, L. A., additional, Cebeira, M. J., additional, Bermejo, N., additional, Riesco, S., additional, Mendoza, M. C., additional, García-Sanz, R., additional, González-Díaz, M., additional, Hernández-Rivas, J. M., additional, and González-Porras, J. R., additional

Published
2016
Full Text
View/download PDF

22. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies

Author

Lopez-Corral, L., primary, Corchete, L. A., additional, Sarasquete, M. E., additional, Mateos, M. V., additional, Garcia-Sanz, R., additional, Ferminan, E., additional, Lahuerta, J.-J., additional, Blade, J., additional, Oriol, A., additional, Teruel, A. I., additional, Martino, M. L., additional, Hernandez, J., additional, Hernandez-Rivas, J. M., additional, Burguillo, F. J., additional, San Miguel, J. F., additional, and Gutierrez, N. C., additional

Published
2014
Full Text
View/download PDF

23. Mutation Status and Immunoglobulin Gene Rearrangements in Patients from Northwest and Central Region of Spain with Chronic Lymphocytic Leukemia

Author

González-Gascón y Marín, I., primary, Hernández, J. A., additional, Martín, A., additional, Alcoceba, M., additional, Sarasquete, M. E., additional, Rodríguez-Vicente, A., additional, Heras, C., additional, de las Heras, N., additional, Fisac, R., additional, García de Coca, A., additional, de la Fuente, I., additional, Hernández-Sánchez, M., additional, Recio, I., additional, Galende, J., additional, Martín-Núñez, G., additional, Alonso, J. M., additional, Hernández-Rivas, J. M., additional, and González, M., additional

Published
2014
Full Text
View/download PDF

24. Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance

Author

Thiago, L. S., primary, Perez-Andres, M., additional, Balanzategui, A., additional, Sarasquete, M. E., additional, Paiva, B., additional, Jara-Acevedo, M., additional, Barcena, P., additional, Sanchez, M. L., additional, Almeida, J., additional, Gonzalez, M., additional, San Miguel, J. F., additional, Garcia-Sanz, R., additional, and Orfao, A., additional

Published
2013
Full Text
View/download PDF

25. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

Author

Puig, N, primary, Sarasquete, M E, additional, Balanzategui, A, additional, Martínez, J, additional, Paiva, B, additional, García, H, additional, Fumero, S, additional, Jiménez, C, additional, Alcoceba, M, additional, Chillón, M C, additional, Sebastián, E, additional, Marín, L, additional, Montalbán, M A, additional, Mateos, M V, additional, Oriol, A, additional, Palomera, L, additional, de la Rubia, J, additional, Vidriales, M B, additional, Bladé, J, additional, Lahuerta, J J, additional, González, M, additional, Miguel, J F S, additional, and García-Sanz, R, additional

Published
2013
Full Text
View/download PDF

26. Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication

Author

Misiewicz-Krzeminska, I., primary, Sarasquete, M. E., additional, Quwaider, D., additional, Krzeminski, P., additional, Ticona, F. V., additional, Paino, T., additional, Delgado, M., additional, Aires, A., additional, Ocio, E. M., additional, Garcia-Sanz, R., additional, San Miguel, J. F., additional, and Gutierrez, N. C., additional

Published
2012
Full Text
View/download PDF

27. Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients

Author

Santamaria, C., primary, Muntion, S., additional, Roson, B., additional, Blanco, B., additional, Lopez-Villar, O., additional, Carrancio, S., additional, Sanchez-Guijo, F. M., additional, Diez-Campelo, M., additional, Alvarez-Fernandez, S., additional, Sarasquete, M. E., additional, de las Rivas, J., additional, Gonzalez, M., additional, San Miguel, J. F., additional, and del Canizo, M. C., additional

Published
2012
Full Text
View/download PDF

28. Genomic analysis of high-risk smoldering multiple myeloma

Author

Lopez-Corral, L., primary, Mateos, M. V., additional, Corchete, L. A., additional, Sarasquete, M. E., additional, de la Rubia, J., additional, de Arriba, F., additional, Lahuerta, J.-J., additional, Garcia-Sanz, R., additional, San Miguel, J. F., additional, and Gutierrez, N. C., additional

Published
2012
Full Text
View/download PDF

30. Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients

Author

Sarasquete, M. E., primary, Gutierrez, N. C., additional, Misiewicz-Krzeminska, I., additional, Paiva, B., additional, Chillon, M. C., additional, Alcoceba, M., additional, Garcia-Sanz, R., additional, Hernandez, J. M., additional, Gonzalez, M., additional, and San-Miguel, J. F., additional

Published
2010
Full Text
View/download PDF

31. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia

Author

Santamaria, C., primary, Chillon, M. C., additional, Garcia-Sanz, R., additional, Balanzategui, A., additional, Sarasquete, M. E., additional, Alcoceba, M., additional, Ramos, F., additional, Bernal, T., additional, Queizan, J. A., additional, Penarrubia, M. J., additional, Giraldo, P., additional, San Miguel, J. F., additional, and Gonzalez, M., additional

Published
2008
Full Text
View/download PDF

32. Minimal Residual Disease Studies in Multiple Myeloma Patients Achieving Complete Remission after Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) by RQ-PCR.

Author

Sarasquete, M. E., primary, García-Sanz, R., additional, Balanzategui, A., additional, Martínez-Sánchez, P., additional, Martínez-López, J., additional, Chillón, M. C., additional, González, D., additional, Lahuerta, J.J., additional, Armellini, A., additional, Martín-Jiménez, P., additional, Alcoceba, M., additional, Blázquez, L., additional, Fernández, C., additional, González, M., additional, and San Miguel, J.F., additional

Published
2004
Full Text
View/download PDF

33. The Cell Expression of PML-RARa at Diagnosis Has a Marginal Correlation with Prognosis in Patients with Acute Promyelocytic Leukemia (APL).

Author

Fernández, Carina, primary, Chillón, Carmen, primary, Blázquez, Lorena, primary, Ramos, F., primary, Fernández-Calvo, J., primary, Rayón, C., primary, Balanzategui, A., primary, Martín-jiménez, P., primary, Alcoceba, M., primary, Sarasquete, M. E., primary, Armellini, A., primary, García-Sanz, R., primary, González, M., primary, and Miguel, J.F. San, primary

Published
2004
Full Text
View/download PDF

35. ROLE OF HLA SPECIFICITIES IN FOLLICULAR LYMPHOMA

Author

Alcoceba, M., Garca-Alvarez, M., Sara Alonso-Alvarez, Prieto-Conde, I., Jimenez, C., Sarasquete, M. E., Chillon, M. C., Balanzategui, A., Maldonado, R., Hernandez-Ruano, M., Anton, A., Corral, R., Puig, N., Martin, A., Vidriales, M. B., Gutierrez, N., Caballero, M. D., Garcia-Sanz, R., Marin, L., and Gonzalez, M.

36. Impact of the immunophenotypical and molecular response evaluated by flow cytometry and fluorescent pcr in the follow up of multiple myeloma patients achieving conventional complete response after autologous stem cell transplantation

Author

Martinez-Lopez, J., Montejano, L., Martinez-Sanchez, P., Sarasquete, M. E., Garcia-Sanz, R., Montalban, M. A., Rapado, I., Garcia-Larana, J., Martinez, R., Besalduch, J., Hernandez, B., Sanchez-Godoy, P., Sureda, A., Blade, J., La Rubia, J., Ayala, R., Miguel, J. San, and Juan José Lahuerta

38. NEW GENERATION ALTERNATIVES FOR THE DETECTION AND QUANTIFICATION OF MINIMUM RESIDUAL DISEASE (EMR) IN PATIENTS WITH MULTIPLE MYELOMA

Author

Medina-Herrera, A., Jimenez, C., Puig, N., Sanchez-Vega, B., Gonzalez, M., Ayala, R., Sarasquete, M. E., Paiva, B., Cedena, M. T., Rapado, I., Rosinol, L., Ocio, E. M., Oriol, A., Miller, J., Fernandez-Ruicobo, F., Hernandez, M. T., Martinez Martinez, R., Mateos, M., Juan José Lahuerta, Blade, J., San Miguel, J. F., Martinez-Lopez, J., and Garcia-Sanz, R.

41. APPLICATION OF THE LYMPHOTRACK MASS SEQUENCING KIT (R) IN THE STUDY OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA. COMPARISON WITH CMF AND ASO-PCR

Author

Medina, A., Jimenez, C., Sarasquete, M. E., Alcoceba, M., Chillon, M. C., Balanzategui, A., Corral, R., Prieto, I., Garcia Alvarez, M., Marin, L., Gutierrez, N., Mateos, M. V., Puig, N., Martinez Lopez, J., Juan José Lahuerta, Ruiz Heredia, Y., Ayala, R., Escalante, F., Blade, J., Oriol, A., Flores Montero, J., Orfao, A., San Miguel, J., Gonzalez, M., and Garcia Sanz, R.

Catalog

Books, media, physical & digital resources
See catalog results